VC and Investment
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Today's issue
Refine Search
Biotechnology
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Biotechnology
Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024
Pharmaceutical
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
Biotechnology
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
Pharmaceutical
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
Pharmaceutical
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
Pharmaceutical
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Biotechnology
In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024
Biotechnology
Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024
Biotechnology
In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024
Pharmaceutical
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Boston, USA-based Upstream Bio, a biotech developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, has made an impressive start to life as a public-listed company.00000 14 October 2024
Biotechnology
A start-up has in-licensed the allogeneic CAR-T portfolio of the world’s largest pharma company in a deal that grabbed the attention of the drugmaking world on Tuesday. 3 April 2018
Pharmaceutical
The CARB-X accelerator, a project devoted to early stage antibacterial R&D, is to partner with Osaka-based Shionogi. 22 March 2018
Biotechnology
TCR2 Therapeutics, an immuno-oncology (I-O) company claiming to be developing a new class of T cell receptor (TCR)-based cellular therapies for both solid tumors and blood cancers, has completed an oversubscribed Series B financing of $125 million. 22 March 2018
Pharmaceutical
Although there have been some new drugs approved for the treatment of Duchenne muscular dystrophy (DMD) in the past year or two, none are seen as being particularly effective therapy. 21 March 2018
Biotechnology
In a second European cancer financing deal this year, Canada’s Portage Biotech (OTC: PTGEF) says that it has made an investment in iOx Therapeutics, UK-based immuno-oncology company. 8 March 2018
Biotechnology
A new partnership between Austrian biotech Themis Bioscience and Oslo-based CEPI – the Coalition for Epidemic Preparedness Innovations – will see an investment of up to $37.5 million going into vaccine development and manufacturing for Lassa fever and MERS. 8 March 2018
Biotechnology
US biotech Rubius Therapeutics, which calls itself the world’s only company developing natural blood that has been made therapeutically active, has completed an oversubscribed $100 million crossover financing, adding to the $120 million that it raised nine months ago. 1 March 2018
Pharmaceutical
Boston, USA-based Gelesis has raised $30 million to support development of its pipeline of gastrointestinal disorder therapies, which includes candidates targeting type 2 diabetes and non-alcoholic steatohepatitis (NASH). 1 March 2018
Biotechnology
The biologics arm of UK-based AstraZeneca is putting six molecules from its early-stage inflammation and autoimmunity programs at the heart of a newly formed company, called Viela Bio. 28 February 2018
Biotechnology
ORIC Pharmaceuticals, a US clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, has completed a $50 million Series C preferred stock financing. 21 February 2018
Pharmaceutical
Merck KGaA today announced the creation of ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. 20 February 2018
Pharmaceutical
A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered around the SEE-Tx platform to develop treatments for rare metabolic diseases. 20 February 2018
Biotechnology
Polish biotech firm Selvita pleased investors with its announcement of a major share 2.2 million placement, sending its shares 4.68% higher to 64.80 zlotys 19 February 2018
Pharmaceutical
Spain-based ABAC Therapeutics, a leader in pathogen-specific antibiotics, announced today the closing of a 16 million euros (~$20 million) Series A round. 15 February 2018
Biotechnology
US biotech startup Moderna Therapeutics, a company specializing in messenger RNA (mRNA), has raised $500 million in a fundraising that values the firm at more than $7 billion. 2 February 2018
Pharmaceutical
UCB and a syndicate of Belgian and international investors have founded a new firm, Syndesi Therapeutics, to be based at the Centre d’Entreprises et d’Innovation (CEI) in Louvain-la-Neuve, Belgium. 1 February 2018
Pharmaceutical
Boston, USA-based cancer company Partner Therapeutics (PTx) has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from French pharma major Sanofi (Euronext: SAN). 1 February 2018
Biotechnology
The Bonn, Germany-based Life Science Inkubator is bringing to life a previously axed research project originating at Merck KGaA. 1 February 2018
Pharmaceutical
China’s Food and Drug Administration recently issued many new polices to push healthcare reform and drug innovation in the country. One of them is to acknowledge foreign trial data and hire more staff to speed up Investigational New Drug (IND) and New Drug Applications (NDA) approval, writes The Pharma Letter’s China correspondent Wang Fangqing. 29 January 2018
Biotechnology
Poland’s leading biotech firm Selvita has confirmed its intention to conduct a secondary public offering. 26 January 2018
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze